Compare UNTY & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UNTY | KROS |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 538.6M | 584.9M |
| IPO Year | 2014 | 2020 |
| Metric | UNTY | KROS |
|---|---|---|
| Price | $55.08 | $11.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $65.00 | $21.86 |
| AVG Volume (30 Days) | 25.1K | ★ 302.8K |
| Earning Date | 04-14-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.23% | N/A |
| EPS Growth | 39.66 | ★ 146.00 |
| EPS | ★ 1.40 | N/A |
| Revenue | N/A | ★ $243,864,000.00 |
| Revenue This Year | $12.14 | N/A |
| Revenue Next Year | $9.56 | $2,751.79 |
| P/E Ratio | $38.65 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $41.67 | $9.79 |
| 52 Week High | $57.30 | $22.55 |
| Indicator | UNTY | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 61.77 | 49.43 |
| Support Level | $50.54 | $10.64 |
| Resistance Level | $57.03 | $12.43 |
| Average True Range (ATR) | 1.17 | 0.70 |
| MACD | 0.19 | -0.05 |
| Stochastic Oscillator | 99.85 | 61.98 |
Unity Bancorp Inc is a bank holding company that serves as a holding company for Unity Bank. The Company has elected to become a financial holding company pursuant to regulations of the Board of Governors of the Federal Reserve System (the FRB). The Company's primary business is ownership and supervision of the Bank. The Company and the Bank derive a majority of their revenue from net interest income (i.e., the difference between the interest received on loans and securities and the interest paid on deposits and borrowings). The Company, through the Bank, conducts a traditional and community-oriented commercial banking business and services, personal and business checking accounts, time deposits, money market accounts, savings accounts, credit cards, automated teller service, and others.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.